Video: PRODIGY Animation
PRODIGY is a Medtronic-sponsored, prospective, multi-center, international cohort study to identify patients at risk of opioid-induced respiratory depression (OIRD), a potentially life-threatening form of respiratory compromise. The PRODIGY study found a 46 percent incidence of respiratory depression in patients on the GCF receiving parenteral opioids.¹ Learn more at www.Medtronic.com/PRODIGY (19-PM-0254) 1. Khanna AK, Bergese S, Jungquist CR, et al. Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. Anesth Analg. Vol. 131(4). October 2020."